Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories

D J Thirion1, L A Zanetti

  • 1Henry Ford Health System Anticoagulation Clinic, Sterling Heights, Michigan 48310, USA.

Pharmacotherapy
|January 21, 2000
PubMed

Insights

A vaginal yeast infection treatment with miconazole may cause bleeding in patients taking warfarin. This drug interaction can prolong clotting time, necessitating awareness among healthcare providers.

Area of Science:

  • Pharmacology
  • Internal Medicine
  • Gynecology

Background:

  • Anticoagulation therapy with warfarin is common for preventing thromboembolic events.
  • Miconazole is frequently used to treat vaginal yeast infections.

Observation:

  • A patient on warfarin therapy developed ecchymosis (bruising) during treatment for a vaginal yeast infection.
  • Laboratory tests showed a prolonged prothrombin time in the patient.

Findings:

  • The observed bleeding and prolonged prothrombin time suggest a potential drug interaction between warfarin and vaginally administered miconazole.
  • Miconazole may inhibit the metabolism of warfarin, leading to increased anticoagulant effects.

Implications:

  • Healthcare professionals must consider potential drug interactions when prescribing miconazole, particularly to patients on anticoagulation.
  • Vaginal miconazole use in patients receiving warfarin requires careful monitoring for signs of bleeding and altered coagulation parameters.
  • Further investigation into the pharmacokinetic interactions between topical miconazole and warfarin is warranted.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...